Generated by AI
Pacific Biosciences of California, Inc. is a life sciences technology company that develops, manufactures, and markets advanced genetic sequencing solutions. Its core offering is HiFi long-read sequencing, supported by Single Molecule, Real-Time technology designed to produce highly accurate, detailed views of DNA. The company provides sequencing instruments, consumables, reagent kits, sample-preparation products, binding kits, and related laboratory solutions for genomic analysis workflows. Its technologies serve research institutions, clinical laboratories, pharmaceutical and biotechnology companies, agricultural organizations, and other customers working with complex genetic material. Applications include human genome and germline analysis, oncology research, infectious disease and microbiology studies, plant and animal sciences, population genomics, and other fields requiring comprehensive DNA characterization. Pacific Biosciences of California, Inc. occupies a specialized role in the genomics market by supporting long-read analysis, which can help researchers investigate genetic regions and structural variations that may be difficult to resolve with shorter sequencing methods.
Website1305 O’Brien Drive
Menlo Park, CA, 94025
United States
The latest articles about PACB.
Pacific Biosciences of California Inc (PACB) posted $40.6 million in Q3 2026 revenue, narrowed full-year guidance to $155--$160 million, and reaffirmed a path to cash flow breakeven in 2028.
Summary of Nov 12's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Summary of Oct 7's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about PACB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.